{Reference Type}: Journal Article
{Title}: The Recent Development of Luteolin-loaded Nanocarrier in Targeting Cancer.
{Author}: Kar B;Rout SR;Halder J;Mahanty R;Mishra A;Saha I;Kanti Rajwar T;Dash P;Das C;Pradhan D;Kumar Rai V;Ghosh G;Rath G;
{Journal}: Curr Pharm Des
{Volume}: 0
{Issue}: 0
{Year}: 2024 Jul 3
{Factor}: 3.31
{DOI}: 10.2174/0113816128313713240628063301
{Abstract}: <B>BACKGROUND: </B>Luteolin (LUT), a naturally occurring flavonoid found in vegetables, fruits, and herbal medicines, has been extensively studied for its pharmacological activities, including anti-proliferative and anticancer effects on various cancer lines. It also exhibits potent antioxidant properties and pro-apoptotic activities against human cancers. However, its therapeutic potential is hindered by its poor solubility in water (5 μg/ml at 45°C) and low bioavailability. This research on the development of luteolin-loaded nanocarrier aims to overcome these limitations, thereby opening up new possibilities in cancer treatment.<BR><B>METHODS: </B>This paper covers several nanoformulations studied to increase the solubility and bioavailability of LUT. The physicochemical characteristics of the nanoformulation that influence luteolin's solubility and bioavailability have been the subject of more in-depth investigation. Furthermore, it examines how LUT's anti-inflammatory and antioxidant properties aid in lessening the side effects of chemotherapy.<BR><B>RESULTS: </B>Most nanoformulations, including phytosomes, lipid nanoparticles, liposomes, protein nanoparticles, polymer micelles, nanoemulsions, and metal nanoparticles, have shown promising results in improving the solubility and bioavailability of LUT. This is a significant step forward in enhancing the therapeutic potential of LUT in cancer treatment. Furthermore, the study found that LUT's ability to scavenge free radicals can significantly reduce the side effects of cancer treatment, further highlighting its potential to improve patient outcomes.<BR><B>CONCLUSIONS: </B>Nanoformulations, because of their unique surface and physiochemical properties, improve the solubility and bioavailability of LUT. However, poor in-vitro and in-vivo correlation and scalability of nanoformulations need to be addressed to achieve good clinical performance of LUT in oncology.